New drug aims to fortify bones in postmenopausal women
NCT ID NCT07178327
Summary
This is a first-in-human study to test the safety and effects of a new drug called LYN101. It will first be given as a single dose to healthy volunteers, and then as multiple doses to postmenopausal women with low bone mass. The main goal is to see how the body handles the drug and to check for any side effects, while also measuring early signs of its impact on bone health.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPOROTIC FRACTURE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Shanghai Sixth People's Hospital
Shanghai, China
-
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, 233060, China
Conditions
Explore the condition pages connected to this study.